Stock Analiz

NewAmsterdam Pharma Co N.V. (NAMS) financials: revenue, earnings and cash flow

Fiscal 2020–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Net income in fiscal 2025 was -$204M, a net margin of -905.7%; the best year in this period was 2020 with -$7M.

Over the twelve months to September 30, 2026, revenue was $26M and net income -$205M.

Free cash flow was -$148M in fiscal 2025 and positive in 1 of the 6 years shown.

Revenue, profit and cash flow by year

Revenue
2022: $103M20222023: $14M20232024: $46M20242025: $23M2025$23M
Net income
2020: -$7M20202021: -$42M20212022: -$23M20222023: -$177M20232024: -$242M20242025: -$204M2025-$204M
Free cash flow
2020: -$7M20202021: -$30M20212022: $10M20222023: -$141M20232024: -$159M20242025: -$148M2025-$148M
EPS (diluted)
2020: $-0.0620202021: $-0.3520212022: $-0.1920222023: $-1.4820232024: $-2.0120242025: $-1.702025$-1.70

Income statement

Fiscal yearTTM202520242023202220212020
Revenue$26M$23M$46M$14M$103M——
Gross profit———————
Operating income—-$226M-$176M-$183M-$4M-$35M-$7M
Net income-$205M-$204M-$242M-$177M-$23M-$42M-$7M
EPS (diluted)$-1.68$-1.70$-2.01$-1.48$-0.19$-0.35$-0.06
R&D—$142M$151M$159M$87M$29M—
Revenue growth—−50.6%+223.4%−86.3%———

Cash flow

Fiscal yearTTM202520242023202220212020
Operating cash flow-$150M-$148M-$159M-$141M$11M-$30M-$7M
Capital spending-$395000-$246000-$672000-$24000-$221000-$24000-$15952
Free cash flow-$151M-$148M-$159M-$141M$10M-$30M-$7M
Dividends paid—$0$0$0$0$0$0
Buybacks———————
Stock-based pay—$59M$34M$25M$4M$1M—

Balance sheet

Fiscal yearTTM202520242023202220212020
Cash—$636M$834M$340M$468M$60M$10M
Debt—$202000$448000$60000$126000——
Equity—$683M$758M$288M$430M-$114M-$73M
Total assets—$769M$865M$347M$478M$68M—
Shares (diluted)122M120M120M120M120M120M120M

Margins and returns

Fiscal yearTTM202520242023202220212020
Gross margin———————
Operating margin—-1002.9%-386.9%-1298.6%-3.5%——
Net margin-789.9%-905.7%-530.2%-1255.8%-22.0%——
FCF margin-581.6%-657.8%-349.5%-1002.4%10.2%——
ROIC—-26.1%-23.3%-50.1%-0.7%——
ROE—-29.8%-31.9%-61.4%-5.3%36.7%9.7%

Frequently asked questions

What is NewAmsterdam Pharma Co’s annual revenue?

$23M in fiscal 2025 and $26M over the twelve months to September 30, 2026.

How much profit does NewAmsterdam Pharma Co make?

Net income was -$204M in fiscal 2025 (net margin -905.7%).

Is NewAmsterdam Pharma Co’s revenue growing?

No: revenue fell 50.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.